Supernus Pharmaceuticals
Launch date
Employees
Market cap
CAD2.3b
Enterprise valuation
CAD1.9b (Public information from Sep 2024)
Share price
$32.13 SUPN
Rockville Maryland (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 520m | 580m | 667m | 608m | 622m | 626m | 691m |
| % growth | 32 % | 11 % | 15 % | (9 %) | 2 % | 1 % | 10 % |
| EBITDA | 210m | 120m | 150m | 109m | 127m | 111m | 157m |
| % EBITDA margin | 40 % | 21 % | 22 % | 18 % | 20 % | 18 % | 23 % |
| Profit | 127m | 53.4m | 60.7m | 1.3m | 15.9m | (49.4m) | 38.4m |
| % profit margin | 24 % | 9 % | 9 % | - | 3 % | (8 %) | 6 % |
| EV / revenue | 2.5x | 2.7x | 2.9x | 2.6x | 3.1x | 3.1x | 2.8x |
| EV / EBITDA | 6.3x | 12.9x | 12.9x | 14.5x | 15.3x | 17.5x | 12.4x |
| R&D budget | 76.0m | 90.5m | 74.6m | 91.6m | - | - | - |
| R&D % of revenue | 15 % | 16 % | 11 % | 15 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$17.5m | Series A | ||
| N/A | $30.0m | Debt | |
| N/A | $42.0m | Growth Equity VC | |
| N/A | N/A | IPO | |
* | N/A | $90.0m | Post IPO Debt |
* | N/A | $350m | Post IPO Debt |
* | $150m | Post IPO Debt | |
| Total Funding | CAD81.1m | ||
Related Content
Recent News about Supernus Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Supernus Pharmaceuticals
Edit
ACQUISITION by Supernus Pharmaceuticals Oct 2021
ACQUISITION by Supernus Pharmaceuticals Sep 2018